Recent advances in CAR-T therapy for the treatment of acute myeloid leukemia
Chimeric antigen receptor T-cell (CAR-T) therapy, which has demonstrated notable efficacy against B-cell malignancies and is approved by the US Food and Drug Administration for clinical use in this context, represents a read more significant milestone in cancer immunotherapy.However, the efficacy of CAR-T therapy for the treatment of acute myeloid